OverviewSuggest Edit

Heat Biologics is a clinical-stage company focused on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers.
The Company's ImPACT therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. ImPACT effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. This therapy is applicable to a wide range of cancers.
Heat is currently conducting multiple clinical trials in two indications with its ImPACT therapy based products, HS-410 to treat Non-Muscle Invasive Bladder Cancer (NMIBC) and HS-110 to treat Non-Small Cell Lung Cancer (NSCLC).

TypePublic
Founded2008
HQDurham, NC, US
Websiteheatbio.com

Latest Updates

Employees (est.) (Dec 2018)30(+58%)
Revenue (FY, 2020)$2.9 M(-3%)
Share Price (Mar 2021)$6.9 (-2%)
Cybersecurity ratingAMore

Key People/Management at Heat Biologics

Jeffrey Wolf

Jeffrey Wolf

Founder, Chairman and CEO
John Prendergast

John Prendergast

Lead Independent Director
George Peoples

George Peoples

Chief Medical Advisor
John Monahan

John Monahan

Director
Edward B. Smith

Edward B. Smith

Director
William L. Ostrander

William L. Ostrander

Vice President of Finance and Secretary
Show more

Heat Biologics Office Locations

Heat Biologics has offices in Durham and Morrisville
Durham, NC, US (HQ)
801 Capitola Dr #12
Morrisville, NC, US
627 Davis Dr #400
Show all (2)

Heat Biologics Financials and Metrics

Heat Biologics Revenue

Heat Biologics's revenue was reported to be $2.95 m in FY, 2020
USD

Revenue (FY, 2020)

2.9m

Net income (FY, 2020)

(26.4m)

EBIT (FY, 2020)

(26.1m)

Market capitalization (30-Mar-2021)

175.8m

Closing stock price (30-Mar-2021)

6.9

Cash (31-Dec-2020)

10.9m

EV

166.6m
Heat Biologics's current market capitalization is $175.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

40.6k341.6k1.5m5.8m3.0m2.9m

General and administrative expense

2.4m4.0m4.4m4.1m6.4m7.0m9.4m14.9m

R&D expense

2.7m2.9m2.6m9.3m8.3m16.2m13.0m12.9m

Operating expense total

5.2m6.8m7.0m13.5m14.6m23.3m22.4m27.9m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

11.0k6.5k9.7k9.1k220.2k24.2k411.3k470.8k752.5k1.1m1.8m701.1k342.5k6.4k901.9k593.2k

General and administrative expense

438.2k737.5k1.0m1.0m832.1k1.3m893.2k947.4k1.0m1.1m820.6k1.5m1.6m1.2m1.8m1.4m1.6m3.3m1.9m2.0m3.3m1.8m

R&D expense

689.0k992.4k533.6k849.4k1.0m503.6k587.2k677.2k500.2k454.9k559.2k1.8m2.2m1.8m2.9m3.5m4.4m3.2m3.4m3.1m2.8m2.8m

Operating expense total

1.1m1.8m1.5m1.9m1.9m1.8m1.5m1.6m1.5m1.5m1.4m3.3m3.7m3.0m4.7m4.8m6.0m6.5m5.3m5.1m6.1m4.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

4.6m3.7m4.9m7.8m9.8m22.2m9.0m10.9m

Accounts Receivable

1.8m82.3k14.8k28.5k35.0k177.2k

Prepaid Expenses

1.1m869.0k2.0m961.3k420.3k1.8m

Inventories

1.7m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

3.0m23.6m2.7m6.0m10.3m8.2m10.0m7.1m8.5m11.1m8.3m4.3m9.0m24.7m21.0m17.9m13.8m9.3m20.7m20.7m

Accounts Receivable

131.8k2.0k10.0k1.4k5.4k14.3k68.2k79.0k77.4k37.3k144.1k27.0k

Prepaid Expenses

500.4k800.5k862.9k668.2k986.3k648.3k440.0k529.0k279.9k273.3k1.9m1.7m4.0m2.5m818.7k684.2k734.8k537.7k593.9k

Current Assets

3.5m24.4m20.3m17.6m22.2m15.9m12.5m7.6m9.1m11.4m8.6m6.2m10.6m28.7m23.5m24.4m20.2m15.8m27.1m47.6m
USDQ2, 2013

Debt/Equity

0.7 x

Debt/Assets

0.2 x

Financial Leverage

3.2 x
Show all financial metrics

Heat Biologics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Heat Biologics Online and Social Media Presence

Embed Graph

Heat Biologics News and Updates

Heat Biologics stock more than doubles after 'positive' trial data of its lung cancer treatment

Shares of Heat Biologics Inc. more than doubled in very active trading Tuesday, after the biopharmaceutical company focused on modulating the immune system reported "positive" interim data from a Phase 2 trial of its lung cancer treatment. The stock soared 115% toward a seven-month high ahead of th…

Thinking about buying stock in Nio, Heat Biologics, Bed Bath & Beyond, Interpace Biosciences, or Lululemon Athletica?

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, HTBX, BBBY, IDXG, and LULU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Heat Biologics, Co-Diagnostics, Penn National Gaming, Boxlight Corp, or Intec Pharma?

NEW YORK, Aug. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTBX, CODX, PENN, BOXL, and NTEC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Lyft Inc, Heat Biologics, Canopy Growth Corp, Sorrento Therapeutics, or Delta Air Lines?

NEW YORK, Aug. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LYFT, HTBX, CGC, SRNE, and DAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Heat Biologics, IZEA Worldwide, Ocugen Inc, Trevena Inc, or Delta Air Lines?

NEW YORK, July 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTBX, IZEA, OCGN, TRVN, and DAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in BioNTech, Endeavour Silver Corp, Biomerica, Heat Biologics, or Tonix Pharmaceuticals?

NEW YORK, July 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNTX, EXK, BMRA, HTBX, and TNXP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Heat Biologics Blogs

Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jef…

Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today annou…

Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumab DURHAM, NC / ACCESSWIRE / February 9, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical c…

Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Spike specific CD8+ and CD4+ T-cell memory responses observed 30- and 60- days post vaccination DURHAM, NC / ACCESSWIRE / January 27, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune …

Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announ…

Heat Biologics Commences Manufacturing Process for ZVX-60

DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announ…
Show more

Heat Biologics Frequently Asked Questions

  • When was Heat Biologics founded?

    Heat Biologics was founded in 2008.

  • Who are Heat Biologics key executives?

    Heat Biologics's key executives are Jeffrey Wolf, John Prendergast and George Peoples.

  • How many employees does Heat Biologics have?

    Heat Biologics has 30 employees.

  • What is Heat Biologics revenue?

    Latest Heat Biologics annual revenue is $2.9 m.

  • What is Heat Biologics revenue per employee?

    Latest Heat Biologics revenue per employee is $98.3 k.

  • Who are Heat Biologics competitors?

    Competitors of Heat Biologics include InxMed, Rain Therapeutics and Pangaea Oncology.

  • Where is Heat Biologics headquarters?

    Heat Biologics headquarters is located at 801 Capitola Dr #12, Durham.

  • Where are Heat Biologics offices?

    Heat Biologics has offices in Durham and Morrisville.

  • How many offices does Heat Biologics have?

    Heat Biologics has 2 offices.